上海交通大学医学院附属瑞金医院
Ruijin Hospital
在本站收录的 53 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
上海交通大学医学院附属瑞金医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文牵头 1 项开放试验
- 肝细胞癌Hepatocellular carcinoma35 篇牵头论文牵头 3 项开放试验
- 胃癌Stomach cancer96 篇牵头论文牵头 13 项开放试验
- 骨肉瘤Osteosarcoma13 篇牵头论文牵头 1 项开放试验
- 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
- 神经母细胞瘤Neuroblastoma2 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma22 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia11 篇牵头论文牵头 4 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
- β 地中海贫血Beta thalassaemia0 篇牵头论文
- 血友病 AHaemophilia A5 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- 烟雾病Moyamoya disease2 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
- 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
- 法布雷病Fabry disease3 篇牵头论文
- Alport 综合征Alport syndrome1 篇牵头论文
- IgA 肾病IgA nephropathy4 篇牵头论文牵头 2 项开放试验
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文
未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、再生障碍性贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、庞贝病、杜氏肌营养不良、白塞病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。
上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- 分期
- 不分期
- 开始
- 2024-06
- 登记号
- NCT06596954
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2023-01
- 登记号
- NCT05978193
年龄 18 岁 至 未注明(登记的条件)
牵头:上海市胸科医院;另有 1 家列出的医院为研究中心上海
- 正在招募Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- 分期
- III期
- 开始
- 2019-09
- 登记号
- NCT04135664
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海市胸科医院;另有 5 家列出的医院为研究中心上海、南昌、天津
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文22
- The Clinical Value of hsa_circ_0000419 in Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
- Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled
- Sparing lymphocytes during preoperative adjuvant radiotherapy for oesophageal squamous cell carcinoma (SPARE): protocol for an open-label, randomised controlled trial.
- CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
- Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.
- TROAP promotes esophageal squamous cell carcinoma progression via the PI3K/AKT pathway.
- Radiomics applications in the modern management of esophageal squamous cell carcinoma.
- Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.
- Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).
- Retrospective Analysis of CT-based Habitat Analysis for Predicting pCR and Survival of ESCC Treated by Neoadjuvant Chemoradiotherapy and Esophagectomy.
- The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort.
- Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.
- A novel computational model ITHCS for enhanced prognostic risk stratification in ESCC by correcting for intratumor heterogeneity.
- Real-world evaluation of multimodal treatment practice in older oesophageal cancer patients.
- A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors.
- Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis.
- High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
- Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
- Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".
- Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
- Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
- Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population.
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
- Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
- Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)21
- Association of Skeletal Muscle and Adiposity Measured by Computed Tomography with Toxicity and pCR in Esophageal Squamous Cell Carcinoma Receiving Standardized Neoadjuvant Chemoradiotherapy
- The Predictive Value of Pretreatment Peripheral T-Lymphocyte Subsets for Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma Patients Undergoing Neoadjuvant Chemoradiotherapy: A Prospective Cohort Analysis
- Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis of a Prospective Cohort
- 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
- 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- A propensity score–matched analysis to evaluate the benefit of adjuvant therapy on disease progression of esophageal squamous cell carcinoma after R0 esophagectomy.
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).
- P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- Prediction of Response to Neoadjuvant Chemoradiotherapy Combined with Pembrolizumab in Esophageal Squamous Cell Carcinoma with CT/FDG PET Radiomic Signatures Based on Machine Learning Classification
- Sarcopenia as a Predictor of Neoadjuvant Therapy-Related Toxicity in Esophageal Squamous Cell Carcinoma Patients
- Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).
- Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14
- Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial
- Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.2%。
上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- 分期
- II期
- 开始
- 2025-11
- 登记号
- NCT07331883
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院;另有 2 家列出的医院为研究中心上海、长春
- 正在招募The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- 分期
- 未注明
- 开始
- 2024-12
- 登记号
- NCT06746194
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- 分期
- 未注明
- 开始
- 2023-03
- 登记号
- NCT05870969
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT06954467
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙
- 即将招募29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- 分期
- 未注明
- 开始
- 2025-08
- 登记号
- NCT07100236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文35
- RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1 -mutated hepatocellular carcinoma.
- Radiomics with Machine Learning Improves the Prediction of Microscopic Peritumoral Small Cancer Foci and Early Recurrence in Hepatocellular Carcinoma.
- Suppression of pseudogene MT2P1 transcription induced by E2F7 inhibits hepatocellular carcinoma cell proliferation and facilitates apoptosis via preserving its parental gene.
- Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.
- Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.
- Preoperative Multifrequency MR Elastography for Stratifying Wnt/β-Catenin Pathway and Microvascular Invasion Phenotypes in Hepatocellular Carcinoma.
- Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery.
- A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR-II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma.
- Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
- Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.
- The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
- FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.
- METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation.
- Three-Dimensional Multifrequency MR Elastography for Microvascular Invasion and Prognosis Assessment in Hepatocellular Carcinoma.
- Risk predictive model for the development of hepatocellular carcinoma before initiating long-term antiviral therapy in patients with chronic hepatitis B virus infection.
- Alternative splicing-related long noncoding RNA ANRIL facilitates hepatocellular carcinoma by targeting the miR-199a-5p/SRSF1 axis and impacting Anillin.
- Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study.
- Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.
- Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.
- Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short-term recurrence of hepatocellular carcinoma post-radical surgery.
- Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
- Editorial for "LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study".
- Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis.
- Circular RNA circ SET domain containing 2 (circSETD2) inhibits hepatocellular carcinoma cell proliferation and invasion in vivo and in vitro.
- Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
- PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.
- E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription.
- Pseudogene SNRPFP1 derived long non-coding RNA facilitates hepatocellular carcinoma progress in vitro by sponging tumor-suppressive miR-126-5p.
- Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma.
- Immunological effect of irreversible electroporation on hepatocellular carcinoma.
- Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.
- PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma.
- ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.
- Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning.
- The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
中文论文(未计入)3
- [Value of albumin RNAscope in situ hybridization in diagnosis and differential diagnosis of hepatocellular carcinoma].
- [Standardized screening and early imaging diagnosis strategies for hepatocellular carcinoma].
- [Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 96 篇,占 1.0%。
上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 23
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- 分期
- II期
- 开始
- 2026-04
- 登记号
- NCT07556640
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT06519591
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- 分期
- I/II期
- 开始
- 2025-06
- 登记号
- NCT07025889
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07026149
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07366528
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海
- 正在招募Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- 分期
- 未注明
- 开始
- 2025-06
- 登记号
- NCT07824479
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT07867392
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06597526
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2020-09
- 登记号
- NCT05140746
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- 分期
- 未注明
- 开始
- 2026-04
- 登记号
- NCT07554742
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- 分期
- I期
- 开始
- 2026-11
- 登记号
- NCT07923396
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2025-03
- 登记号
- NCT06888037
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- 分期
- III期
- 开始
- 2021-09
- 登记号
- NCT04384601
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06901531
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、郑州
- 正在招募Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- 分期
- 未注明
- 开始
- 2025-06
- 登记号
- NCT07068529
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- 分期
- 未注明
- 开始
- 2025-06
- 登记号
- NCT07076979
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- 分期
- II/III期
- 开始
- 2024-02
- 登记号
- NCT06221748
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛
- 正在招募Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06679244
年龄 18 岁 至 80 岁(登记的条件)
牵头:复旦大学附属华山医院;另有 2 家列出的医院为研究中心上海
- 正在招募Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- 分期
- III期
- 开始
- 2023-04
- 登记号
- NCT05918094
年龄 18 岁 至 75 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、广州、成都、武汉、郑州
- 正在招募AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- 分期
- 未注明
- 开始
- 2023-09
- 登记号
- NCT06035250
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛
- 正在招募A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- 分期
- I期
- 开始
- 2022-06
- 登记号
- NCT05365581
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州
- 即将招募Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07746830
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文96
- Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.
- Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.
- Machine Learning-Driven SERS Analysis Platform for Accurate and Rapid Diagnosis of Peritoneal Metastasis from Gastric Cancer.
- Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immuno
- Loss of DRD5P2 in hypoxia attenuates Rock2 degradation to promote EMT and gastric cancer metastasis.
- USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.
- Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.
- Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.
- Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.
- Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.
- Gallstones, cholecystectomy, and cancer risk: an observational and Mendelian randomization study.
- Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.
- Resveratrol targets mitochondrial USP36-SOD2 to induce autophagy-ferroptosis and inhibit gastric cancer progression.
- FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis.
- SIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer.
- Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
- Malignant gastric glomus tumor with heterochronous liver metastases: a case report and review of the literature.
- Multi-Omics Analysis Reveals OBSCN as a Key Modulator of Tumor Microenvironment, Microbial Signatures and Clinical Outcomes in Gastric Cancer.
- Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers.
- Overlap Versus π-Shaped Esophagojejunostomy After Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Study.
- Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma.
- The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer.
- Improving diagnosis and outcome prediction of gastric cancer via multimodal learning using whole slide pathological images and gene expression.
- The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
- PHF10 inhibits gastric epithelium differentiation and induces gastric cancer carcinogenesis.
- Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids.
- The effect of self-designed metabolic equivalent exercises on cancer-related fatigue in patients with gastric cancer: A randomized controlled trial.
- SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.
- In-hospital outcomes of older patients with gastric cancer and their risk factors: large comprehensive institution-based study.
- Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10.
- Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.
- Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer.
- Cytotoxic effects of NIR responsive chitosan-polymersome layer coated melatonin-upconversion nanoparticles on HGC27 and AGS gastric cancer cells: Role of the ROS/PI3K/Akt/mTOR signaling pathway.
- Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer.
- GC-CDSS: Personalized gastric cancer treatment recommendations system based on knowledge graph.
- Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
- Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.
- Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.
- Tumor-mesothelium HOXA11-PDGF BB/TGF β1-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer.
- VPS35 promotes gastric cancer progression through integrin/FAK/SRC signalling-mediated IL-6/STAT3 pathway activation in a YAP-dependent manner.
- Latest guideline of endoscopic submucosal dissection of early gastric cancer may not be suitable for Chinese patients: retrospective study findings from two centers.
- CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients.
- Efficacy and prognostic value of delta radiomics on dual-energy computed tomography for gastric cancer with neoadjuvant chemotherapy: a preliminary study.
- BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
- Androgen receptor promotes cell stemness via interacting with co-factor YAP1 in gastric cancer.
- The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
- HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer.
- VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer.
- Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer.
- Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.
- Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.
- Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling.
- A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.
- Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.
- Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
- Intra-abdominal fat volume estimation by multi-detector rows computed tomography: relevance in surgical fellowship training program in Shanghai: a retrospective study.
- Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation.
- Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity.
- CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.
- Long non-coding RNA NUT family member 2A-antisense RNA 1 sponges microRNA-613 to increase the resistance of gastric cancer cells to matrine through regulating oxidative stress and vascular endothelial growth factor A.
- A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis.
- Initial screening of gastric cancer using oral contrast-enhanced trans-abdominal ultrasonography in rural asymptomatic individuals.
- LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling.
- CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells.
- Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.
- Endoscopic closure of a large gastric mucosal defect after endoscopic submucosal dissection using a novel endoscopic string-with-knotter suture device.
- Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy.
- CHRDL2 promotes cell proliferation by activating the YAP/TAZ signaling pathway in gastric cancer.
- Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.
- Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.
- Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
- A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial.
- Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
- A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
- Atranorin driven by nano materials SPION lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-/GPX4 axis and its expression.
- Application Value of 4K High-Definition System in Laparoscopic Gastrectomy: Preliminary Results and Initial Experience.
- Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.
- The dynamic alteration of transcriptional regulation by crucial TFs during tumorigenesis of gastric cancer.
- Pangenomic analysis of Chinese gastric cancer.
- A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.
- An xception model based on residual attention mechanism for the classification of benign and malignant gastric ulcers.
- Quantifying the cell morphology and predicting biological behavior of signet ring cell carcinoma using deep learning.
- Assessment of liver metastases radiomic feature reproducibility with deep-learning-based semi-automatic segmentation software.
- Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
- A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.
- LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation.
- Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.
- ATP5B promotes the metastasis and growth of gastric cancer by activating the FAK/AKT/MMP2 pathway.
- A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.
- YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis.
- Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction.
- Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.
- The Validity of the GLIM Criteria for Malnutrition in Hospitalized Patients with Gastric Cancer.
- Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer.
- Collective dynamics of gastric cancer cells in fluid.
- The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer.
中文论文(未计入)14
- [Current status and prospects of minimally invasive surgical treatment for gastric cancer].
- [Strategies for supra-pancreatic lymph node dissection in laparoscopic gastric cancer surgery].
- [Clinical application of intraperitoneal chemotherapy ports in patients with gastric cancer and peritoneal metastases].
- [Clinical value and implementation strategies of normothermic intraperitoneal and systemic chemotherapy (NIPS) in the treatment of gastric cancer with peritoneal metastasis].
- [Key measures to improve the efficacy of diagnosis and treatment of gastric cancer with peritoneal metastasis].
- [Analysis of discordant results between multiplex fluorescence PCR-capillary electrophoresis for microsatellite instability (MSI) detection and immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in gastrointestinal aden
- [Clinical significance of combined therapy with immune checkpoint inhibitor in perioperative treatment for locally advanced gastric cancer or adenocarcinoma of gastroesophageal junction].
- [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
- [Preliminary analysis of the promotion effect of laparoscopic standardized surgical treatment for gastric cancer in regional medical centers in Shanghai].
- [Small steps to thousands of miles: a tribute to Chinese laparoscopic gastric cancer surgery].
- [Digestive tract reconstruction after laparoscopic proximal gastrectomy for adenocarcinoma of esophagogastric junction].
- [Strategies of chemotherapy for peritoneal metastasis of gastrointestinal cancer].
- [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
- [Current status and prospect of perioperative therapy for locally advanced gastric cancer].
它在 ClinicalTrials.gov 上的全部试验(任何状态)58
- GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
- Effect of a Self-designed MET Exercise Intervention on Cancer-related Fatigue in Patients With Gastric Cancer
- Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
- Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
- Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
- Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
- In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors
- Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
- ctDNA Screening in Advanced HER2 Positive Gastric Cancer
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
- Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- mFLOT Chemotherapy as First-line Treatment in GC
- Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
- Escorting Octogenarian for Gastric Cancer Surgery
- Early Detection of Postoperative Anastomotic Leak by CT
- Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
- A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Performing Laparoscopic Surgery for Colorectal and Gastric Cancer Outside the Primary Registered Medical Institution
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
- 分期
- II期
- 开始
- 2023-06
- 登记号
- NCT06114225
年龄 10 岁 至 65 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文13
- Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.
- Chemotherapeutic drug-triggered AEP-cleaved G3BP1 orchestrates stress granules/nucleoli/mitochondria in osteosarcoma.
- Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.
- Spectral computed tomography-guided radiotherapy of osteosarcoma utilizing BiOI nanosheets.
- Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
- Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
- Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.
- Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma.
- DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment.
- Current Status and Prospects of Clinical Treatment of Osteosarcoma.
- Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.
- Development and analysis of long non-coding RNA-associated competing endogenous RNA network for osteosarcoma metastasis.
- Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with Single Ultra-Low Dose.
中文论文(未计入)1
早期论文(2016–2020 年)15
- MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
- Isolation of extracellular vesicle with different precipitation-based methods exerts a tremendous impact on the biomarker analysis for clinical plasma samples.
- Establishment of a dynamic osteosarcoma biobank: Ruijin experience.
- Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
- Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.
- ASO Author Reflections: Metastatic Biopsy of Osteosarcoma with Circulating RNA.
- Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.
- Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.
- Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth.
- Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.
- Primary, cardiac, fibroblastic osteosarcoma: A case report.
- Patellar height influences knee function in patients with aggressive bone tumors of the proximal tibia after endoprosthetic reconstruction.
- Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
- Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.
- Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
- Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma
- Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
- Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)5
- [Analysis and comparison of the clinical features and prognosis between extra - gastrointestinal stromal tumors and duodenal gastrointestinal stromal tumors].
- [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].
- Identifying therapeutic targets in gastric cancer: the current status and future direction.
- Facilitating retroflexed endoscopic full-thickness resection through loop-mediated or rope-mediated countertraction (with videos).
- Comparison of the post-operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi-center prospective cohort study.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 22 篇,占 1.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- 分期
- I期
- 开始
- 2026-09
- 登记号
- NCT07914556
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2025-12
- 登记号
- NCT07294625
年龄 18 岁 至 未注明(登记的条件)
牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州
- 正在招募A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- 分期
- I期
- 开始
- 2023-03
- 登记号
- NCT05759793
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- 分期
- IV期
- 开始
- 2022-03
- 登记号
- NCT05201781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文22
- Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
- Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.
- Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.
- Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.
- Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.
- Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
- Challenges facing CAR T-cell immunotherapy in multiple myeloma.
- Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.
- Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.
- Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.
- Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.
- Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
- PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
- Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
- Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
- Integrative analysis of an endoplasmic reticulum stress-related signature in multiple myeloma.
- Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
- Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
- Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
- SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.
- Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
中文论文(未计入)7
- [Characteristics and Risk Analysis of COVID-19 Infection in Patients with Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation].
- [Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era].
- [Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma].
- [Research progress in targeting GPRC5D for the treatment of multiple myeloma].
- [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
- [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
- [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
- Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.9%。
上海有 9 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07838714
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- 分期
- II期
- 开始
- 2024-12
- 登记号
- NCT06718244
年龄 16 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- 分期
- 不分期
- 开始
- 2025-09
- 登记号
- NCT07087847
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07301138
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 即将招募Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- 分期
- I期
- 开始
- 2024-11
- 登记号
- NCT06641024
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Resolving Leukemia Heterogeneity and Lineage Aberrations with HematoMap.
- Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.
- Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α.
- BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review.
- Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.
- Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.
- Transcription factor 12-mediated self-feedback regulatory mechanism is required in DUX4 fusion leukaemia.
- Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
- Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.
- Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
- Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
- A Multi-center Retrospective Study of INO Treating B-ALL
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)5
- POS0387 NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATE CYTOKINE STORM IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASE BY PROMOTING STING-MEDIATED MYELOPOIEIS
- POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT
- Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement
- The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis
- Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 7 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募β-Thalassemia Treatment With KL003 Cell Injection
- 分期
- I/II期
- 开始
- 2024-04
- 登记号
- NCT06280378
年龄 3 岁 至 35 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、天津
- 正在招募A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- 分期
- I期
- 开始
- 2024-01
- 登记号
- NCT06465550
年龄 3 岁 至 35 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、南宁、广州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- β-Thalassemia Treatment With KL003 Cell Injection
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
- Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 5 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文5
- Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.
- Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms.
- Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.
- Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
- Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
早期论文(2016–2020 年)11
- Maternal microchimerism protects hemophilia A patients from inhibitor development.
- In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A.
- [A case of acquired hemophilia A with multiple superficial blistering skin disorders as the main manifestation].
- [Optimized AAV package and experimental application of recombinant AAV8/hFⅧ for gene therapy on hemophilia A mice].
- Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.
- Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.
- Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.
- Spectrum and origin of mutations in sporadic cases of haemophilia A in China.
- Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis.
- AccuCopy quantification combined with pre-amplification of long-distance PCR for fast analysis of intron 22 inversion in haemophilia A.
- Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- China ADVATE PTP Study
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 4 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肺淋巴管平滑肌瘤病
Lymphangioleiomyomatosis2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 2 篇,占 4.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 6 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 6 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
这些数字背后的记录
牵头的论文3
- A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
- Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients.
- Quantitative evaluation of retinal and choroidal changes in Fabry disease using optical coherence tomography angiography.
中文论文(未计入)2
早期论文(2016–2020 年)1
其他疾病
Alport 综合征
Alport syndrome2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 5 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of Telitacicept in IgAN
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06654596
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- 分期
- 未注明
- 开始
- 2020-12
- 登记号
- NCT04858724
年龄未注明(登记的条件)
牵头:上海交通大学医学院附属瑞金医院上海
- 正在招募A Study of SHR-2173 in Participants With Primary IgA Nephropathy
- 分期
- II期
- 开始
- 2026-03
- 登记号
- NCT07354932
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、广州
- 正在招募A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- 分期
- III期
- 开始
- 2025-07
- 登记号
- NCT06963827
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.
- Uncovering Rare Coding Variants in IgA Nephropathy.
- Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.
- A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.
早期论文(2016–2020 年)9
- A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy.
- Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.
- IgA Nephropathy Susceptibility Loci and Disease Progression.
- A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
- [The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients].
- Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.
- Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.
- Bilateral Posterior Scleritis Presenting as the First Manifestation of Immunoglobulin A Nephropathy: Case Report and Review of the Literature.
- Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
- Efficacy and Safety of Telitacicept in IgAN
- The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
- Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
- Bortezomib for Treating Glomerular Diseases
- Rituximab and RASi in Patients with IgAN
- A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
- A Study of SHR-2173 in Participants With Primary IgA Nephropathy
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
这些数字背后的记录
牵头的论文2
联系这家医院
出示给工作人员或司机的院名卡
上海交通大学医学院附属瑞金医院
Ruijin Hospital
上海
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。